Johnson & Johnson's second quarter revenue of 20.8 billion US dollars | anticancer drug sales contributed the most

Pharmaceutical Network July 19th In the second quarter of 2018, Johnson & Johnson's revenue was 20.8 billion US dollars, of which global cancer drug sales increased by 42% to 2.46 billion US dollars.

Recently, Johnson & Johnson announced the financial situation of the second quarter of 2018. medicine The business performed best, far exceeding expectations.

Compared with the same period of 2017, Johnson & Johnson's revenue increased by 10.6 percentage points to reach US$20.8 billion in the quarter, exceeding analysts' expectations of US$20.39 billion. The pharmaceutical business increased the most, with sales reaching US$10.4 billion, up 20% from the same period last year. Stelara and Kytiga, Darzalex and Imbruvica, the leading drugs for the treatment of Crohn's disease, contributed the most. In this quarter, Johnson & Johnson's global cancer drug sales reached US$2.46 billion, up 42% from the same period last year. The global revenue of the multiple myeloma drug Darzalex skyrocketed 80% to $511 million.

Johnson & Johnson CEO Alex Gorsky said in his speech: 'The fourth quarter of Johnson & Johnson's performance is mainly attributed to the growth of the pharmaceutical and medical device business. In this area, we not only have market-leading products, but also develop new strategies for achieving sustainable growth.'

In the second quarter of 2018, sales of Johnson & Johnson's medical device business increased by 3.7% and revenues reached US$7 billion. Sales of consumer goods increased by only 0.7% and revenues were US$3.5 billion. baby The product line was the worst performer, with global revenues down 7.7 percentage points. Gorsky said the consumer goods business was disappointing, but he revealed that Johnson & Johnson will remodel its baby brand in August 2018.

Recently, a jury in Missouri, USA, sentenced Johnson to pay a record $4.69 billion in damages to 22 women, as the company's talcum powder, including baby powder, containing asbestos, caused these women to develop ovarian cancer. This Gorsky said that Johnson & Johnson still has confidence in its baby talcum powder, saying that 'Johnson has sold baby talcum powder for more than 100 years, this is a trustworthy product'.

This quarter, Johnson & Johnson's net income reached 4 billion US dollars, equivalent to 1.45 US dollars per share. After depreciation and other special expenses, its revenue reached 5.7 billion US dollars, equivalent to 2.10 US dollars per share, higher than Wall Street analysts forecast 2.07 US dollars.